AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25808103 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride 2 mg daily for 24 weeks
Number of subjects: 361
Study 25808103 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily for 24 weeks
Number of subjects: 361
Study 25808103 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride 2 mg daily for 12 weeks
Number of subjects: 361
Study 25808103 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily for 12 weeks
Number of subjects: 361
Study 24050532 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic upper pole heminephroureterectomy (LHNU)
Number of subjects: 27
Study 24050532 — intervention group
Group type: COMPARATOR
Intervention: Open surgery upper pole heminephroureterectomy (OHNU)
Number of subjects: 27
Study 21386088 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy (TRT) using transdermal 2% testosterone gel
Number of subjects: 220
Study 21386088 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy (TRT)
Number of subjects: 220
Study 21386088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 18789844 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg/day)
Number of subjects: 30
Study 18789844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 17542407 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii (250 mg dissolved in 5 ml of water orally twice daily for 7 days)
Number of subjects: 27
Study 17542407 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Number of subjects: 27
Study 17542407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 14718904 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic low frequency (6 Hz) motor stimulation
Number of subjects: 30
Study 14718904 — intervention group
Group type: COMPARATOR
Intervention: Submotor transcutaneous electrical nerve (TENS) stimulation
Number of subjects: 30
Study 11265082 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue applied to lymphatic structures prior to closure
Number of subjects: 0
Study 11265082 — intervention group
Group type: COMPARATOR
Intervention: Closure without fibrin glue
Number of subjects: 0
Study 9430014 — intervention group
Group type: EXPERIMENTAL
Intervention: Colpermin
Number of subjects: 110
Study 9430014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 8516521 — intervention group
Group type: COMPARATOR
Intervention: Morphine 0.075 mg/kg i.v. every 3 hours after operation (Group A)
Number of subjects: 20
Study 8516521 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral blockade 15 ml of 0.37‐5% bupivacaine with 1:200.000 adrenaline (Group B)
Number of subjects: 20
Study 3121179 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentinan (LNT) in combination with tegafur (FT), LNT dosage: 2 mg weekly, FT dosage: 600 mg/day
Number of subjects: 164
Study 3121179 — intervention group
Group type: COMPARATOR
Intervention: Tegafur (FT) alone
Number of subjects: 164
Study 30428881 — intervention group
Group type: EXPERIMENTAL
Intervention: CARE's Community Score Card© intervention
Number of subjects: 46
Study 30428881 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study 28122510 — intervention group
Group type: EXPERIMENTAL
Intervention: Film + 16-week exercise program
Number of subjects: 60
Study 28122510 — intervention group
Group type: COMPARATOR
Intervention: 16-week exercise-only program
Number of subjects: 60
Study 28122510 — intervention group
Group type: EXPERIMENTAL
Intervention: Godin Leisure-time Exercise Questionnaire
Number of subjects: 60
Study 28122510 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews
Number of subjects: 60
Study 26158245 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium at the initiation of weaning
Number of subjects: 70
Study 23299364 — intervention group
Group type: EXPERIMENTAL
Intervention: EZ-Blocker (EZB)
Number of subjects: 100
Study 23299364 — intervention group
Group type: COMPARATOR
Intervention: Left-sided double-lumen tube (DLT)
Number of subjects: 100
Study 20834043 — intervention group
Group type: EXPERIMENTAL
Intervention: rMV + PT
Number of subjects: 30
Study 20834043 — intervention group
Group type: COMPARATOR
Intervention: PT alone
Number of subjects: 30
Study 18325720 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized dietary assessments
Number of subjects: 41
Study 18325720 — intervention group
Group type: COMPARATOR
Intervention: Interviewer administered dietary assessments
Number of subjects: 41
Study 18325720 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized assessments
Number of subjects: 41
Study 16579700 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive local oxygen therapy
Number of subjects: 30
Study 16579700 — intervention group
Group type: COMPARATOR
Intervention: Systemic antibiotics (amoxicillin, clavulanic acid, and metronidazole) without oxygen therapy
Number of subjects: 30
Study 12757074 — intervention group
Group type: EXPERIMENTAL
Intervention: Pubovaginal sling (group A)
Number of subjects: 26
Study 12757074 — intervention group
Group type: COMPARATOR
Intervention: Vaginal wall sling (group B)
Number of subjects: 26
Study 10473768 — intervention group
Group type: EXPERIMENTAL
Intervention: In-phase mode along both X- and Y-axes
Number of subjects: 0
Study 10473768 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-phase mode along both X- and Y-axes
Number of subjects: 0
Study 10473768 — intervention group
Group type: EXPERIMENTAL
Intervention: In-phase mode in sagittal plane motions
Number of subjects: 0
Study 10473768 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-phase mode along both axes in sagittal plane motions
Number of subjects: 0
Study 8764115 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (amoxicillin 500 mg three times a day for 2 weeks; metronidazole 400 mg three times a day for 2 weeks; bismuth subsalicylate 262 mg four times a day for 2 weeks, followed by 262 mg every day for 4-12 months)
Number of subjects: 84
Study 8764115 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation (30 mg every day for 4-12 months)
Number of subjects: 84
Study 8764115 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid supplementation (1 g twice a day for 4-12 months)
Number of subjects: 84
Study 8764115 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid or beta-carotene supplementation
Number of subjects: 84
Study 2071126 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg clotrimazole vaginal pessary
Number of subjects: 23
Study 2071126 — intervention group
Group type: COMPARATOR
Intervention: 150 mg fluconazole capsule
Number of subjects: 23
Study 2071126 — intervention group
Group type: EXPERIMENTAL
Intervention: C glabrata or C krusei
Number of subjects: 23
Study 6680215 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intra-arterial infusion of 3-5 mg/day methotrexate to a total dose of 90-120 mg
Number of subjects: 142
Study 6680215 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 142
Study 6680215 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality treatment
Number of subjects: 142
Study 31060534 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulimia Nervosa (BN) patients
Number of subjects: 53
Study 31060534 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls (HCs)
Number of subjects: 53
Study 28067707 — intervention group
Group type: EXPERIMENTAL
Intervention: DPE
Number of subjects: 120
Study 28067707 — intervention group
Group type: COMPARATOR
Intervention: CSE
Number of subjects: 120
Study 28067707 — intervention group
Group type: COMPARATOR
Intervention: EPL
Number of subjects: 120
Study 26031787 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Intelligences Teaching Approach (MITA)
Number of subjects: 90
Study 26031787 — intervention group
Group type: COMPARATOR
Intervention: Conventional teaching
Number of subjects: 90
Study 23283029 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg daily for 1 month)
Number of subjects: 185
Study 23283029 — intervention group
Group type: COMPARATOR
Intervention: Control (no aspirin)
Number of subjects: 185
Study 20589404 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentin desensitizer
Number of subjects: 64
Study 20589404 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser
Number of subjects: 64
Study 20589404 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser
Number of subjects: 64
Study 20589404 — intervention group
Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 64
Study 19827055 — intervention group
Group type: EXPERIMENTAL
Intervention: OLM+CCB combination therapy
Number of subjects: 0
Study 19827055 — intervention group
Group type: COMPARATOR
Intervention: OLM monotherapy
Number of subjects: 0
Study 16760779 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive retractor
Number of subjects: 8
Study 16760779 — intervention group
Group type: COMPARATOR
Intervention: Open retractor
Number of subjects: 8
Study 15076257 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 28
Study 15076257 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed amphetamine salts (Adderall)
Number of subjects: 28
Study 15076257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 11874821 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA (50 mg/m(2)/d) for 3 months
Number of subjects: 20
Study 11874821 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 20
Study 10213101 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 weeks external splinting
Number of subjects: 29
Study 10213101 — intervention group
Group type: COMPARATOR
Intervention: 4 weeks external splinting
Number of subjects: 29
Study 8666469 — intervention group
Group type: EXPERIMENTAL
Intervention: Life Review Program
Number of subjects: 0
Study 8666469 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 2281806 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 1010
Study 2281806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1010
Study 2281806 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 1010
Study 524943 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine 1 mcg.kg‐1 body weight.minute‐1
Number of subjects: 10
Study 524943 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine 5 mcg.kg‐1 body weight.minute‐1
Number of subjects: 10
Study 524943 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (control)
Number of subjects: 10
Study 6842336 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (1 mg/kg) intravenously
Number of subjects: 20
Study 6842336 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 30382872 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 30382872 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene
Number of subjects: 0
Study 30382872 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture + Clomiphene
Number of subjects: 0
Study 30382872 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 27235521 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-based patient-specific matched guides (PSG)
Number of subjects: 137
Study 27235521 — intervention group
Group type: COMPARATOR
Intervention: CT-based patient-specific matched guides (PSG)
Number of subjects: 137
Study 24838278 — intervention group
Group type: EXPERIMENTAL
Intervention: Word stimuli (auditory streaming BCI)
Number of subjects: 16
Study 24838278 — intervention group
Group type: COMPARATOR
Intervention: Beeps stimuli (auditory streaming BCI)
Number of subjects: 16
Study 22832417 — intervention group
Group type: EXPERIMENTAL
Intervention: 17β‐estradiol (1 mg/day for 1 month, then 2 mg/day for 2 months)
Number of subjects: 22
Study 22832417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 20184589 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide and Valsartan (alone and in combination)
Number of subjects: 9306
Study 18689856 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to a quitline service
Number of subjects: 0
Study 18689856 — intervention group
Group type: COMPARATOR
Intervention: In-practice GP management
Number of subjects: 0
Study 15958834 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole prophylaxis
Number of subjects: 2771
Study 12460134 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiated treatment (n = 450)
Number of subjects: 813
Study 12460134 — intervention group
Group type: COMPARATOR
Intervention: Declined enrollment (n = 363)
Number of subjects: 813
Study 10357543 — intervention group
Group type: EXPERIMENTAL
Intervention: Volar carpal canal route of tendon transfer
Number of subjects: 4
Study 10357543 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral band insertion
Number of subjects: 4
Study 7728486 — intervention group
Group type: EXPERIMENTAL
Intervention: Polidocanol (0.5% or 1% for telangiectasias or spider veins; 3% for varicose veins)
Number of subjects: 16804
Study 7728486 — intervention group
Group type: EXPERIMENTAL
Intervention: Polidocanol
Number of subjects: 16804
Study 1852136 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 100
Study 1852136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 7255509 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg orally, 3 times daily for 4 weeks
Number of subjects: 20
Study 7255509 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated patients)
Number of subjects: 20
Study 31577177 — intervention group
Group type: EXPERIMENTAL
Intervention: Taste-focused labels
Number of subjects: 137842
Study 29070566 — intervention group
Group type: EXPERIMENTAL
Intervention: High-glycemic-load diet (HGLDiet) adherence
Number of subjects: 128
Study 29070566 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar intake
Number of subjects: 128
Study 29070566 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate intake
Number of subjects: 128
Study 29070566 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycemic load
Number of subjects: 128
Study 25425220 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline plasma FGF21 levels
Number of subjects: 9697
Study 25425220 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline plasma FGF21 levels (highest tertile)
Number of subjects: 9697
Study 25425220 — intervention group
Group type: EXPERIMENTAL
Intervention: FGF21 levels added to CVD risk factor model
Number of subjects: 9697
Study 24393479 — intervention group
Group type: EXPERIMENTAL
Intervention: artemether + lumefantrine (AL)
Number of subjects: 251
Study 24393479 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate + sulphamethoxypyrazine-pyrimethamine (AS-SMP)
Number of subjects: 251
Study 24393479 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate + amodiaquine (AS-AQ)
Number of subjects: 251
Study 22181668 — intervention group
Group type: EXPERIMENTAL
Intervention: PVP‐iodine gel (10%)
Number of subjects: 12
Study 22181668 — intervention group
Group type: EXPERIMENTAL
Intervention: PVP‐iodine solution (10%)
Number of subjects: 12
Study 22181668 — intervention group
Group type: COMPARATOR
Intervention: Negative control (no iodine application)
Number of subjects: 12
Study 18793300 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapoxetine
Number of subjects: 1238
Study 18793300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1238
Study 17608679 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-embedding immunolabelling procedure using monoclonal primary antibodies anti-I-CF, anti-III-CF and anti-CS.
Number of subjects: 0
Study 17608679 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-embedding immunolabelling procedure using monoclonal primary antibodies anti-I-CF, anti-III-CF and anti-CS.
Number of subjects: 0
Study 17608679 — intervention group
Group type: EXPERIMENTAL
Intervention: Field emission in lens-SEM analysis
Number of subjects: 0
Study 17608679 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmission electron microscopy (TEM) analysis
Number of subjects: 0
Study 15029469 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine 25 mg
Number of subjects: 14
Study 15029469 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine 100 mg
Number of subjects: 14
Study 15029469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 11486846 — intervention group
Group type: EXPERIMENTAL
Intervention: Carmeda‐coated Maxima‐Plus PRF oxygenator
Number of subjects: 60
Study 11486846 — intervention group
Group type: COMPARATOR
Intervention: Trillium‐coated Affinity oxygenator
Number of subjects: 60
Study 9462572 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 331
Study 9462572 — intervention group
Group type: COMPARATOR
Intervention: Angioplasty
Number of subjects: 331
Study 8168806 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame 15 mg/kg/day
Number of subjects: 48
Study 8168806 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame 45 mg/kg/day
Number of subjects: 48
Study 8168806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 3285215 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term cyclosporine
Number of subjects: 417
Study 3285215 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term cyclosporine followed by azathioprine and prednisolone
Number of subjects: 417
Study 3285215 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine and prednisolone only
Number of subjects: 417
Study 31844963 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided steroid wrist injections
Number of subjects: 45
Study 31844963 — intervention group
Group type: COMPARATOR
Intervention: Consensus statements on clinical indications
Number of subjects: 45
Study 31370873 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-tDCS treatment
Number of subjects: 100
Study 31370873 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 100
Study 29192534 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Language-Action Therapy (ILAT)
Number of subjects: 18
Study 29192534 — intervention group
Group type: COMPARATOR
Intervention: Intensive Naming Therapy (INT)
Number of subjects: 18
Study 25907157 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy with support to taper or discontinue antidepressant treatment (MBCT-TS)
Number of subjects: 424
Study 25907157 — intervention group
Group type: COMPARATOR
Intervention: Maintenance antidepressants
Number of subjects: 424
Study 25907157 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (MBCT-TS and maintenance antidepressants)
Number of subjects: 424
Study 23297921 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory training in interrupted noise (7 sessions of 1 hour each)
Number of subjects: 24
Study 23297921 — intervention group
Group type: COMPARATOR
Intervention: Auditory training in continuous noise (7 sessions of 1 hour each)
Number of subjects: 24
Study 22151936 — intervention group
Group type: COMPARATOR
Intervention: 4% hydroquinone cream
Number of subjects: 29
Study 22151936 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% azelaic acid cream
Number of subjects: 29
Study 19401349 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment
Number of subjects: 912
Study 19401349 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment
Number of subjects: 912
Study 16918640 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 mg/day of konjac ceramide in milk sugar (ceramide group)
Number of subjects: 50
Study 16918640 — intervention group
Group type: COMPARATOR
Intervention: Milk sugar (control group)
Number of subjects: 50
Study 14751655 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg once daily for 6 weeks, then increased to 8 mg for an additional 6 weeks
Number of subjects: 1412
Study 14751655 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 8 mg after up-titration
Number of subjects: 1412
Study 14751655 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril in elderly African-Americans (>65 years of age)
Number of subjects: 1412
Study 14751655 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril in diabetic African-Americans
Number of subjects: 1412
Study 10922421 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 9014
Study 9378691 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 100 mg/day during luteal phase
Number of subjects: 15
Study 9378691 — intervention group
Group type: COMPARATOR
Intervention: Placebo during luteal phase
Number of subjects: 15
Study 7901174 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg of quazepam for eight weeks
Number of subjects: 65
Study 7901174 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg of triazolam for eight weeks
Number of subjects: 65
Study 7901174 — intervention group
Group type: COMPARATOR
Intervention: Placebo for four days followed by placebo for another week
Number of subjects: 65
Study 3982917 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (0.2 mg/kg body weight)
Number of subjects: 30
Study 3982917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30843141 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium 5 μg
Number of subjects: 0
Study 30843141 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium/Olodaterol (2 μg, 5 μg, 10 μg)
Number of subjects: 0
Study 29176462 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered Cognitive Behavioral Therapy (CBT)
Number of subjects: 25
Study 29176462 — intervention group
Group type: COMPARATOR
Intervention: Internet Pain Education
Number of subjects: 25
Study 26014476 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (vegetables packaged with cartoon characters and stickers)
Number of subjects: 24
Study 26014476 — intervention group
Group type: COMPARATOR
Intervention: Control group (generic packaged vegetables)
Number of subjects: 24
Study 23313603 — intervention group
Group type: EXPERIMENTAL
Intervention: High arousal and negative valence (anxious condition)
Number of subjects: 121
Study 23313603 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive valence
Number of subjects: 121